A related question.
Having found no dose-limiting toxicity with Cu67 attached to one targeting agent, can Clarity skip the dose escalatoon stage in therapeutic trials with Cu67 attached to different targeting agents?
- Forums
- ASX - By Stock
- CU6
- Research/Valuation
Research/Valuation, page-205
-
-
- There are more pages in this discussion • 335 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CU6 (ASX) to my watchlist
|
|||||
Last
$6.44 |
Change
0.300(4.89%) |
Mkt cap ! $2.025B |
Open | High | Low | Value | Volume |
$6.20 | $6.50 | $6.19 | $12.16M | 1.893M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 455 | $6.43 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.44 | 1726 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 1559 | 6.430 |
16 | 5208 | 6.420 |
7 | 5768 | 6.410 |
4 | 1746 | 6.400 |
5 | 5390 | 6.390 |
Price($) | Vol. | No. |
---|---|---|
6.440 | 1242 | 6 |
6.450 | 9089 | 10 |
6.460 | 7150 | 6 |
6.470 | 1925 | 2 |
6.480 | 2020 | 3 |
Last trade - 15.34pm 23/07/2024 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online